In colon cancer, under hypoxic conditions, CAF-derived IL-6 activates STAT3 signaling to promote tumor progression or induce drug resistance via a HIF-1a/miR-338-5p/IL-6 feedback loop [54, 55]. Here, HIF1A is linked to neoplasm.